Fluconazole is not affected by gastric pH and may be an alternative for ketoconazole. Didanosine, ddI is an acid-labile compound. Administration of nizatidine prior to didanosine was shown to increase didanosine serum concentrations, although the magnitude was slight. Nizatidine may increase concentrations of salicylates and salicylate AUCs in patients receiving high-dose aspirin therapy. Nizatidine may cause an inhibition of salicylate renal excretion.
Antacids can slightly decrease nizatidine absorption.
Administer at least an hour apart. The incidence of adverse reactions occuring during nizatadine therapy is often no higher than the incidence occuring during placebo administration. GI adverse reactions have been reported in patients receiving nizatidine. Although rare, hepatitis, jaundice, and elevated hepatic enzymes have been reported with nizatidine. Reversible mental status changes, including agitation, delirium, hallucinations, hostility, paranoia, depression, and disorientation, have been reported following nizatidine therapy.